Nonresponse and Progression of Diffuse Keloids to Dupilumab Therapy

Authors

Kevin M. Luk, Henry Ford HealthFollow
Joseph Fakhoury, Henry Ford HealthFollow
David M Ozog, Henry Ford HealthFollow

Recommended Citation

Luk K, Fakhoury J, and Ozog D. Nonresponse and Progression of Diffuse Keloids to Dupilumab Therapy. J Drugs Dermatol 2022; 21(2):197-199

Document Type

Article

Publication Date

2-1-2022

Publication Title

Journal of drugs in dermatology : JDD

Abstract

Th2 cytokines, including IL-4 and IL-13, have been shown to increase TGFβ, promoting fibrosis. A recent study showed keloid improvement in one patient after administration of Dupilumab, an IL-4 receptor alpha-antagonist, for his/her atopic dermatitis. Here, we present two 17-year-old patients with diffuse keloids without improvement after three months of Dupilumab treatment, with one patient experiencing clinical worsening. It is currently unknown if Th2 cytokine blockade in patients with keloids reduces TGFβ synthesis or activation. Future studies are needed to investigate the utility of Th2 cytokine blockade as a potential treatment option for keloids.

Medical Subject Headings

Adolescent; Antibodies, Monoclonal, Humanized; Cytokines; Dermatitis, Atopic; Disease Progression; Female; Humans; Keloid; Male; Treatment Failure

PubMed ID

35133105

Volume

21

Issue

2

First Page

197

Last Page

199